Kyntra Bio, Inc. (KYNB)

Market Cap	24.74M -46.3%
Revenue (ttm)	4.62M -37.2%
Net Income	183.19M
EPS	45.27
Shares Out	4.05M
PE Ratio	0.14
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,564
Open	6.08
Previous Close	5.96
Day's Range	6.08 - 6.26
52-Week Range	5.62 - 11.65
Beta	1.05
Analysts	Buy
Price Target	39.67 (+549.26%)
Est. Earnings	Nov 9, 2026

About KYNB

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 34
• Stock Exchange: Nasdaq
• Ticker Symbol: KYNB
• Website: https://www.kyntrabio.com

Analyst Summary

According to 4 analysts, the average rating for KYNB stock is "Buy." The 12-month stock price target is $39.67, which is an increase of 549.26% from the latest price.

Price Target

$39.67

(549.26% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error